Keywords: AA; arachidonic acid; ADP; adenosine diphosphate; CALR; calreticulin; ET; essential thrombocythemia; HRPR; high on-treatment residual platelet reactivity; JAK; janus kinase; MEA; multiple electrode aggregometry; MPL; myeloproliferative leukemia virus onco
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Polycythemia vera; Echocardiography; Global strain; Systolic function;
Keywords: ASCT; allogeneic stem cell transplantation; DIPSS; Dynamic International Prognostic Scoring System; ET; essential thrombocythemia; GVHD; graft versus host disease; IPSS; International Prognostic Scoring System; MPN; myeloproliferative neoplasm; PMF; prima
Keywords: JAK; Janus kinase; STAT; signal transducers and activators of transcription; EPOR; erythropoietin receptor; TPOR; thrombopoietin receptor; G-CSFR; granulocyte colony stimulating factor receptor; γc; common gamma chain; SCID; severe combined immunodeficie
Keywords: nowotwory mieloproliferacyjne; mutacje JAK2; mutacja JAK2 V617F; czerwienica prawdziwa; nadpÅytkowoÅÄ samoistna; Myeloproliferative neoplasm; JAK2 mutation; JAK2 V617F mutation; Polycythemia vera; Essential thrombocythemia;
Keywords: AML; acute myeloid leukemia; ASCT; allogeneic stem cell transplant; BETi; bromodomain and extra terminal domain inhibitor; CR; complete remission; DIPSS; Dynamic International Prognostic Scoring System; ET; essential thrombocythemia; FAB; French-American-
Keywords: Cytokines; Signal transduction; Drug development; Inflammation; Autoimmunity; Therapy; JAK; Janus Kinase; STAT; Signal transducer and activator of transcription; NF-kB; nuclear factor kappa-light-chain-enhancer of activated B cells; MAPK; Mitogen activate
Keywords: JAK2V617F mutation; Myeloproliferative neoplasms; JAK2 inhibitors; JAK-STAT signaling; Myelofibrosis; Polycythemia vera; Mutant calreticulin;
Keywords: Myeloproliferative disorders; Essential thrombocythemia; Polycythemia vera; Chronic myelogenous leukemia; Primary myelofibrosis;
Keywords: Polycythemia vera; Essential thrombocythemia; Lipocalin 2; Thrombosis;
Keywords: Essential thrombocythemia; Hemorrhage; Polycythemia vera; Racial; Thrombosis
Keywords: Anagrelide; Antiplatelet therapy; Essential thrombocythemia; Hydroxyurea; Interferon; Polycythemia vera; Ruxolitinib
Keywords: Myeloproliferative neoplasms; Polycythemia vera; Essential thrombocytosis; Myelofibrosis; JAK2 mutation;
Keywords: ALK; anaplastic lymphoma kinase; ALL; acute lymphoblastic leukemia; CLL; chronic lymphocytic leukemia; CML; chronic myelogenous leukemia; CNS; central nervous system; CRC; colorectal cancer; DTC; differentiated thyroid carcinoma; DUSP; dual specificity ph
Keywords: ACI; anemia of chronic inflammation; AD[H]D; attention deficit[/hyperactivity] disorder; ASD; autism spectrum disorder; BMS; burning mouth syndrome; BPAD; bipolar affective disorder; CCS; Cronkhite-Canada syndrome; CFS; chronic fatigue syndrome; CGRP; cal
Keywords: Myeloproliferative neoplasm; Polycythemia vera; Essential thrombocythemia; Myelofibrosis; Vascular complications
Keywords: Bone marrow fibrosis; Essential thrombocythemia; Polycythemia vera; Primary myelofibrosis; Ruxolitinib
Keywords: Essential thrombocythemia; MGUS; Myelofibrosis; Myeloproliferative neoplasm; Polycythemia vera;
Keywords: Myeloproliferative neoplasms (MPN); Myelofibrosis; Polycythemia vera; Essential thrombocythemia; Hematopoietic stem cell transplantation; Ruxolitinib;
Keywords: myeloproliferative neoplasm; leukemic transformation; leukemia etiology; polycythemia vera; essential thrombocythemia; primary myelofibrosis; antineoplastic agents; alkylators; hydroxyurea; radioactive phosphorous; X-ray treatment; JAK2 mutation; risk fac
Keywords: Myeloproliferative disorders; Essential thrombocythemia; Polycythemia vera; Chronic myelogenous leukemia; Primary myelofibrosis;
Keywords: Molecular response; Polycythemia vera; Essential thrombocythemia; Hydroxycarbamide;
Keywords: Heparin-induced thrombocytopenia; Polycythemia vera; 4Ts score
Keywords: Myeloproliferative neoplasms; Polycythemia vera; JAK2-V617F mutation; Simvastatin; Alendronate
Association polyarthrite rhumatoïde et polyglobulie essentielle JAK2 négative : le méthotrexate peut-il aggraver la polyglobulie ?
Keywords: Polyarthrite rhumatoïde; Maladie de Vaquez; Polyglobulie essentielle; Sulfasalazine; Méthotrexate; Rheumatoid arthritis; Vaquez's disease; Polycythemia Vera; Sulfasalazine; Methotrexate;
The real-world outcomes of treating Polycythemia Vera: Physician adherence to treatment guidelines
Keywords: Guideline adherence; Polycythemia Vera; Real-world practice;
SOHO State-of-the-Art Update and Next Questions: MPN
Keywords: Essential thrombocythemia; Midostaurin; Myelofibrosis; Myeloproliferative neoplasms; Pacritinib; Polycythemia vera; Prefibrotic; Ruxolitinib;
Actualités thérapeutiques dans les néoplasies myéloprolifératives non LMC
Keywords: Myélofibrose primitive; polyglobulie de Vaquez; pronostic; thrombocytémie essentielle; traitement; Primary myelofibrosis; Polycythemia vera; prognosis; essential thrombocythemia; treatment;
Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial
Keywords: Myeloproliferative neoplasms; Essential thrombocytosis; Polycythemia vera; Myelofibrosis; Pegylated interferon;
Diagnostic anatomopathologique des néoplasies myéloprolifératives chroniques Ph-
Keywords: Biopsie ostéo-médullaire; fibrose; maladie de Vaquez; myélofibrose primitive; pronostic; thrombocytémie essentielle; Bone marrow biopsy; fibrosis; prognosis; polycythemia vera; primary myelofibrosis; essential thrombocythemia;
A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia
Keywords: Momelotinib; Polycythemia vera; Essential thrombocythemia; Phase 2 study;
Double the Trouble: Acute Coronary Syndrome and Ischemic Stroke in Polycythemia Vera
Keywords: Acute coronary syndrome; Ischemic stroke; Polycythemia vera;
Invited reviewRecommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology
Keywords: Myeloproliferative neoplasm; Polycythemia vera; Essential thrombocythemia; Myelofibrosis; Diagnosis; Monitoring; Prognosis;
The JAK2V617F mutation in normal individuals takes place in differentiating cells
Keywords: AS-PCR; allele specific PCR; AS-RQ-PCR; allele-specific real-time PCR; ddPCR; digital PCR techniques; ARMS; amplification refractory mutation system;  â Ct; delta threshold cycle; Ct; threshold cycle; EPO; erythropoietin; HSC; hematopoietic stem cell;
Hydroxyurea for Treatment of Nephrotic Syndrome Associated With Polycythemia Vera
Keywords: Hydroxyurea; polycythemia vera; myeloproliferative disorder; nephrotic syndrome; proteinuria; focal segmental glomerulosclerosis (FSGS); kidney biopsy; renal function; case report;
Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?
Keywords: Polycythemia vera; Hydroxyurea; Interferon-a; JAK2 inhibitors;
Granulomatous Dermatitis as a Cutaneous Manifestation of Hematologic Disorders: The First Case Associated With Polycythemia Vera and a New Case Associated With Myelodysplasia
Keywords: Granulomatous dermatitis; Myelodysplasia; Myelodysplastic syndrome; Polycythemia vera; Dermatitis granulomatosa; Mielodisplasia; SÃndrome mielodisplásico; Policitemia vera;
Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting
Keywords: (JAK2); Janus kinase 2; (MPN); myeloproliferative neoplasms; (PV); polycythemia vera; (ET); essential thrombocythemia; (PMF); Primary myelofibrosis; (CALR); calreticulin; (HRM); high resolution melting; (CML); chronic myelogenous leukemia; (Hb); hemoglobi
Place du ruxolitinib dans la stratégie thérapeutique des syndromes myéloprolifératifs
Keywords: Ruxolitinib; Syndromes; myéloprolifératifs; Polyglobulie de Vaquez; Myélofibrose; Thérapies ciblées; Inhibiteurs de JAK2; Ruxolitinib; Myeloproliferative; neoplasms; Polycythemia vera; Myelofibrosis; Targeted therapies; JAK2 inhibitors;
SÃndromes mieloproliferativos
Keywords: SÃndromes mieloproliferativos; Leucemia mieloide crónica; Policitemia vera; Trombocitemia esencial; Mielofibrosis primaria; Myeloproliferative diseases; Chronic myeloid leukemia; Polycythemia vera; Essential thrombocythemia; Primary myelofibrosis;
Myeloproliferative neoplasms: Current molecular biology and genetics
Keywords: Myeloproliferative neoplasms; Polycythemia vera; JAK2; CALR;
The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances
Keywords: Polycythemia vera; Essential thrombocythemia; Prefibrotiy/early primary myelofibrosis; Overt primary myelofibrosis; Revision; Clinical aspects;
Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities
Keywords: Myeloproliferative neoplasms; Myelofibrosis; Polycythemia vera; Chromosome aberrations;
Clinical Features of Patients With Philadelphia-Negative Myeloproliferative Neoplasms Complicated by Portal Hypertension
Keywords: Essential thromobocythemia; JAK inhibitor; Myelofibrosis; Polycythemia vera; Thrombosis;
Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis
Keywords: Splanchnic vein thrombosis; Myeloproliferative neoplasm; Bone marrow morphology; Polycythemia vera; Primary myelofibrosis; Essential thrombocythemia
Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden
Keywords: Polycythemia vera; Essential thrombocythemia; Predictor; Thrombosis; Hemorrhage; Time-weighted averages;
SOHO Supplement 2015New Therapeutic Approaches in Polycythemia Vera
Keywords: Hydroxyurea; Interferon; JAK2; Polycythemia vera; Ruxolitinib;
Mechanisms of thrombogenesis in polycythemia vera
Keywords: Janus kinase 2; Polycythemia vera; Thrombosis;
Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms
Keywords: JAK2 mutations; Jordan; Myeloproliferative neoplasms; Polycythemia vera; V617F
Smoking as a contributing factor for development of polycythemia vera and related neoplasms
Keywords: Smoking; Chronic myelomonocytic stimulation; Essential thrombocythemia; Polycythemia vera; Primary myelofibrosis; Myeloproliferative neoplasms MPNs; Thrombosis; Atherosclerosis; NF-κB; JAK-STAT-signaling; IL-8;